Explore ›
Finding
Finding
adverse
Fenofibrate added to simvastatin was associated with a significantly higher rate of liver enzyme elevation (ALT >5x ULN) compared with simvastatin alone (0.6% vs 0.2%, p=0.03), though absolute rates were very low.
| Effect size | 0.6% vs 0.2% |
| Follow-up | 4.7 years |
| Comparator | Placebo added to simvastatin (20-40 mg/day) |
| Effect summary | adverse; 0.6% vs 0.2% |
| Adverse events | liver enzyme elevation (ALT >5x ULN) 0.6% vs 0.2% |
Connected entities
Interventions
Conditions
Outcomes
Source
PMC4509601
The ACCORD-Lipid study: implications for treatment of dyslipidemia in Type 2 diabetes mellitus